top of page

The NEW Post-Acute Care COVID World:  
Emerging Opportunities for Respiratory Therapists

Fredric Seifer, MD


The COVID pandemic has dramatically and irrevocably changed the healthcare landscape for all healthcare professionals. In order to provide healthcare in a safe environment, telemedicine or remote care has quickly emerged as the new standard of healthcare delivery. Respiratory therapy requires the acquisition of highly technical information to prepare the RTs to function successfully in the acute care setting. However, limited time is devoted to preparing the RT to function in the post-acute care/remote care COVID world. The goal of this session is to introduce participants to the emerging skills that RTs will need to master and excel in this exciting new remote care environment. 


Learning Objectives:

  1. Discuss emerging opportunities for engagement and employment in the remote care environment for pulmonary patients

  2.  Discuss foundational modalities necessary to successfully function in the post-acute care space 

  3. Describe new modalities including Dynamic Dialogues, telemedicine, remote patient  monitoring (RPM), emerging portable noninvasive ventilation (NIV) devices 


Faculty Bio:

Fredric Seifer, MD has served as both Medical Director of Population Health, St. Lawrence Health System (SLHS), Potsdam, NY as well as Chief Physician Executive for Innovation and Transformation, Adirondack Health Institute (AHI), Glens Falls, NY. Prior to assuming these roles, Dr. Seifer served as Medical Advisor for Pulmonary Health Innovation for Community Health Systems (CHS), Nashville, TN. Dr. Seifer’s research interests and experience include smoking cessation, pulmonary rehabilitation, idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and non-cystic fibrosis bronchiectasis (NCF-BE). As a recognized thought leader in pulmonary healthcare, Dr. Seifer has served as a member of multiple Advisory Committees both at the state (TennCare) and federal government (NLHEP) level and within the private sector (pharmaceutical 

bottom of page